ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0912

CD11c⁺CD21⁻ Autoimmune-Associated B Cells Derived from Double-Negative IgD⁻CD27⁻ Subsets Exhibit Enhanced IFNLR1 Expression in Systemic Lupus Erythematosus

Roukaya Yaakoub, Diana Alzamareh, Alexander Bae William and Jennifer Barnas, university of rochester, rochester, NY

Meeting: ACR Convergence 2025

Keywords: autoimmune diseases, B-Cell Targets, B-Lymphocyte, interferon

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 27, 2025

Title: (0897–0915) B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster II

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: Autoimmune-associated B cells (ABCs) are increasingly recognized for their role in the pathogenesis of systemic lupus erythematosus (SLE), yet their developmental origins and specific functions remain unclear. Interferon-lambda (IFN-λ), a type III interferon implicated in SLE, may have distinct effects from the well-established pathogenic role of interferon-alpha (IFN-α), still its contribution remains incompletely understood. Prior studies suggest that ABCs—characterized by a CD11c⁺CD21⁻ phenotype—are most prevalent within the double-negative (DN) B-cell subset, which also shows heightened responsiveness to IFN-λ. We hypothesize that CD11c⁺CD21⁻ ABCs, predominantly arising from the DN IgD⁻CD27⁻ B-cell subset, exhibit enhanced responsiveness to IFN-λ, contributing to their pathogenic role SLE through upregulated IFNLR1 expression.

Methods: To investigate the development and function of ABCs, peripheral blood mononuclear cells (PBMCs) were isolated from patients with SLE (n = 18). Flow cytometry was employed to quantify CD11c⁺CD21⁻ ABCs across four B-cell subsets: naïve, switched memory (SM), unswitched memory (USM), and DN. IFNLR1 expression was later assessed within these subsets (n = 3).To explore the intrinsic differentiation potential of ABCs, in vitro stimulation assays were performed using sorted-purified naïve, SM, USM, and DN B cells from healthy donors (HDs) (n = 3). Cells were cultured under ABC-inducing conditions, including B-cell receptor stimulation, R848 (TLR7/8 agonist), IFN-γ, IL-21, and BAFF. Following culture, the induction of CD11c⁺CD21⁻ ABCs and IFNLR1 expression were analyzed by flow cytometry.

Results: Flow cytometric analysis of PBMCs from SLE patients (n = 18) revealed that CD11c⁺CD21⁻ ABCs were most enriched within DN B-cell subset. Their frequency was significantly higher relative to total CD19⁺ B cells compared to other subsets. The mean frequencies of ABCs were 6.46% in DN, 2.59% in USM, 1.37% in naïve, and 0.29% in SM B cells (p < 0.02).In vitro differentiation assays using sorted B-cell subsets from HDs (n = 3) demonstrated that DN and SM B cells exhibited the highest propensity to differentiate into ABCs under stimulatory conditions. The mean frequencies of induced ABCs were 46.2% for DN, 32.4% for SM, 13.4 for naïve and 4.3 for USM B cells.Assessment of IFNLR1 expression showed significantly elevated levels on CD11c⁺CD21⁻ ABCs within the DN subset in SLE patients (p < 0.02). In vitro, ABCs derived from DN B cells exhibited a 6.3-fold increase in IFNLR1 expression under ABC-inducing conditions, compared to 2.5-fold, 1.6-fold, and 1.6-fold increases in ABCs derived from SM, naïve, and USM B cells, respectively.

Conclusion: These findings identify the DN B-cell subset as a key origin of CD11c⁺CD21⁻ autoimmune-associated B cells in SLE and highlight their enhanced capacity for IFNLR1 expression. The preferential differentiation of DN B cells into ABCs, coupled with their heightened responsiveness to IFN-λ, driven by increased IFNLR1 expression, suggests a distinct IFN-λ–mediated pathway in B-cell–driven autoimmunity. This IFN-λ–IFNLR1 axis may represent a novel therapeutic target for modulating B-cell–driven autoimmunity in SLE.


Disclosures: R. Yaakoub: None; D. Alzamareh: None; A. William: None; J. Barnas: None.

To cite this abstract in AMA style:

Yaakoub R, Alzamareh D, William A, Barnas J. CD11c⁺CD21⁻ Autoimmune-Associated B Cells Derived from Double-Negative IgD⁻CD27⁻ Subsets Exhibit Enhanced IFNLR1 Expression in Systemic Lupus Erythematosus [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/cd11c%e2%81%bacd21%e2%81%bb-autoimmune-associated-b-cells-derived-from-double-negative-igd%e2%81%bbcd27%e2%81%bb-subsets-exhibit-enhanced-ifnlr1-expression-in-systemic-lupus-erythematosus/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/cd11c%e2%81%bacd21%e2%81%bb-autoimmune-associated-b-cells-derived-from-double-negative-igd%e2%81%bbcd27%e2%81%bb-subsets-exhibit-enhanced-ifnlr1-expression-in-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology